Lipidic Prodrugs for Drug Delivery: Opportunities and Challenges
Authors:
- Milica MarkovicMilica Markovic
- Shimon Ben-ShabatSBShimon Ben-Shabat
- Arik DahanADArik Dahan
- 13 May 2020
- book chapter
- Published by Taylor & Francis
- p. 113-132
Abstract
Prodrugs present inactive drug precursors intended to undergo enzymatic/chemical transformation in the body, thus liberating the active parent drug (Stella 2004). The strategy of designing a prodrug is used to improve physicochemical features of the drug moiety, and by doing so overcome absorption, distribution, metabolism, excretion and toxicity (ADMET) barriers. In addition, overcoming physicochemical deficiencies leads to improved site specificity, enhanced pharmacological effect, better formulation possibilities and facilitated drug administration (Testa 2009). In the process of prodrug 114development, various changes to polarizability, lipophilicity, H-bonds, steric factors, solubility, permeability, chemical/enzymatic stability and affinity toward enzyme/transporter can be introduced in order to overcome numerous barriers (Rautio et al. 2018).Keywords
This publication has 1 reference indexed in Scilit:
- Improving nucleoside analogs via lipid conjugation: Is fatter any better?Critical Reviews in Oncology/Hematology, 2016